サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1663468

生物製剤受託開発の世界市場：サービスの種類別・生物製剤の種類別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)

Biologics Contract Development Market, By Service Type, By Biologics Type, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
生物製剤受託開発の世界市場：サービスの種類別・生物製剤の種類別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)
出版日: 2025年02月04日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

生物製剤受託開発の市場規模は2024年に75億965万米ドルとなり、2025年から2032年にかけてCAGR 8.94%で拡大

生物製剤受託開発の市場力学

個別化医療に対する需要の高まりが生物製剤受託開発の成長を牽引

個別化医療に対する需要の高まりが、生物製剤受託開発市場の大きな促進要因です。個別化医療は、個人の遺伝子プロファイルに合わせて治療を調整し、有効性を向上させ、副作用を軽減します。米国国立衛生研究所 (NIH) によると、個別化医療の世界市場は2025年までに3兆5,000億米ドルに達すると予測されています。

生物学的治療法が個別化医療の中心となるにつれ、専門的な受託開発サービスの必要性が高まっています。遺伝性疾患やがんの有病率の増加は、生物製剤の需要をさらに高めます。NIHは、世界の約10人に1人が希少疾病に罹患しており、その多くが生物学的治療法を必要としていると推定しています。こうした要因により、バイオ製薬企業は必要な専門知識を利用し、効率的に生産規模を拡大するために、受託開発機関と提携するようになっています。

生物製剤受託開発市場：主な考察

リサーチアナリストの分析によると、世界市場は予測期間 (2025-2032年) に約8.94%のCAGRで毎年成長すると推定されます。

サービスの種類別では、受託製造が2024年に最大の市場シェアを示すと予測されています。

生物製剤の種類別では、2024年にはモノクローナル抗体が生物製剤の主要な種類となります。

地域別では、北米が2024年に収益を生み出す主要市場です。

生物製剤受託開発市場：セグメンテーション分析

世界の生物製剤受託開発市場は、サービスの種類、生物製剤の種類、エンドユーザー、地域に基づいてセグメント化されます。

市場はサービスの種類に基づいて3つのカテゴリーに分けられます：受託研究、受託製造、受託試験の3つです。生物製剤受託開発市場で最も支配的なセグメントは受託製造です。このセグメントは、モノクローナル抗体やワクチンなどの生物製剤の大量生産に対する需要の増加により、大幅な成長を遂げています。受託製造機関 (CMO) は、生物製剤を効率的に製造するために必要な専門知識、施設、設備を、規制遵守を維持しながらバイオ医薬品企業に提供します。生物製剤は細胞培養や発酵などの特殊な工程を必要とするため、これらのサービスをアウトソーシングすることで、企業はコストと市場投入までの時間を削減することができます。特に個別化医療や複雑な疾患に対する生物学的療法の台頭により、拡張性のある製造ソリューションの必要性が高まっており、この分野の重要性は確固たるものとなっています。

市場は生物製剤の種類によって4つのカテゴリーに分類されます：モノクローナル抗体、ワクチン、遺伝子治療、組み換えタンパク質です。生物製剤受託開発市場で最も支配的なセグメントはモノクローナル抗体です。このセグメントは、がん、自己免疫疾患、感染症を含む様々な疾患の治療におけるモノクローナル抗体 (mAb) の需要の増加によりリードしています。 mAbsは特異性が高く、従来の薬剤と比較してより優れた有効性と少ない副作用を提供する標的療法を提供します。バイオテクノロジーの進歩に伴い、多くの新しいmAbが開発され、個別化医療に広く使用されるようになりました。その結果、医薬品開発業務受託機関 (CDO) は、mAbの開発・製造サービスの提供にますます注力するようになっており、この分野は生物製剤受託開発市場で最も顕著な地位を占めています。

生物製剤受託開発市場：地域別分析

北米は、強固な医療インフラ、強力な研究開発能力、生物製剤に対する高い需要に牽引され、生物製剤受託開発市場で大きなシェアを占めています。米国食品医薬品局 (FDA) は生物製剤の規制において重要な役割を果たしており、治療の安全性と有効性を保証しています。北米には主要なバイオ製薬企業、学術機関、受託開発機関があり、生物製剤開発の重要な拠点となっています。米国はがんや自己免疫疾患などの慢性疾患の罹患率が高く、生物製剤の需要をさらに加速させています。さらに、同地域の医療政策は個別化医療のイノベーションと償還を支援しており、生物製剤への多額の投資を引き寄せています。製造・開発サービスを専門のCDOにアウトソーシングする傾向が強まっていることも、市場の成長に拍車をかけています。ゲノミクスとバイオテクノロジーの進歩により、北米は生物製剤の開発と受託サービスでリードし続ける立場にあります。

米国は、高度な医療システム、主要製薬企業、最先端の研究機関によって、生物製剤受託開発の市場で支配的な役割を果たしています。米国食品医薬品局 (FDA) は、生物製剤の安全性と有効性を保証する確立された規制枠組みを提供し、市場への信頼を醸成しています。米国では、がん、糖尿病、自己免疫疾患などの慢性疾患の有病率が高く、生物学的治療の需要を後押ししています。さらに、米国はバイオテクノロジーと医薬品イノベーションの世界的リーダーであり、個別化医療、遺伝子治療、モノクローナル抗体への投資が盛んです。生物製剤の開発と製造を開発業務受託機関 (CDO) に委託する傾向が強まっているため、バイオ医薬品企業はコストを削減し、技術革新に集中することができます。さらに、米国政府による研究資金援助や規制面での優遇措置が、市場情勢をさらに強化しています。精密医療への注目が高まる中、米国の生物製剤受託開発市場は今後も力強い成長軌道を維持すると予想されます。

生物製剤受託開発市場：競合情勢

生物製剤受託開発市場の競合情勢は、先進技術、規制遵守、コスト効率の高いソリューションに注力する複数の主なプレイヤーの存在によって特徴付けられます。Lonza Group、WuXi AppTec、Samsung Biologicsなどの主要企業は、プロセス開発、製造、臨床試験サポートを含む生物製剤開発における広範なサービス提供で市場をリードしています。例えばロンザ・グループは、特にモノクローナル抗体の大規模な生物製剤製造において、最先端の設備と専門知識を提供しています。ウーシー・アプテックは、個別化医療に重点を置いた創薬、開発、製造の統合サービスで知られています。サムスン・バイオロジクスは、最先端のバイオ製造能力と、業務効率と規制遵守に重点を置いています。これらの企業は、製薬会社やバイオテクノロジー企業との強い関係を維持し、生物製剤開発の分野で優先されるパートナーとして位置づけられています。生産規模を拡大し、品質管理を徹底し、進化する規制基準に適応する能力は、競争優位性を高め続けています。

目次

第1章 生物製剤受託開発市場の概要

  • 調査範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 生物製剤受託開発の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 生物製剤受託開発市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 生物製剤受託開発市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 生物製剤受託開発の市場情勢

  • 生物製剤受託開発の市場シェア分析 (2024年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 生物製剤受託開発市場：サービスの種類別

  • 概要
    • セグメント別シェア分析：サービスの種類別
    • 受託研究
    • 受託製造
    • 受託試験

生物製剤受託開発市場：生物製剤の種類別

  • 概要
    • セグメント別シェア分析：生物製剤の種類別
    • モノクローナル抗体
    • ワクチン
    • 遺伝子治療
    • 組み換えタンパク質

第8章 生物製剤受託開発市場：エンドユーザー別

  • 概要
    • セグメント別シェア分析：エンドユーザー別
    • 製薬企業
    • バイオテクノロジー企業
    • 学術・研究機関

第9章 生物製剤受託開発市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋 (APAC)
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ (LATAM)
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ (MEA)
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第10章 主要ベンダー分析：生物製剤受託開発業界

  • 競合ダッシュボード
    • 競合ベンチマーク
    • 競合ポジショニング
  • 企業プロファイル
    • Lonza Group
    • WuXi AppTec
    • Samsung Biologics
    • Catalent
    • Boehringer Ingelheim
    • AbbVie
    • Fujifilm Diosynth Biotechnologies
    • CordenPharma
    • Samsung Biologics
    • Patheon (Thermo Fisher Scientific)
    • Merck KGaA
    • KBI Biopharma
    • Recipharm
    • Minaris Regenerative Medicine
    • Syngene International
    • Rentschler Biopharma
    • Almac Group
    • Emergent BioSolutions

第11章 AnalystViewの全方位的分析

目次
Product Code: ANV4643

REPORT HIGHLIGHT

Biologics Contract Development Market size was valued at US$ 7,509.65 Million in 2024, expanding at a CAGR of 8.94% from 2025 to 2032.

The biologics contract development market refers to the industry where companies outsource the development and manufacturing of biologic drugs to specialized service providers. Biologics are complex products derived from living organisms, including monoclonal antibodies, vaccines, and gene therapies. Contract development organizations (CDOs) offer services ranging from early-stage research, process development, and clinical trials, to large-scale manufacturing. These partnerships help biopharma companies reduce costs, improve efficiency, and access specialized expertise. As the demand for biologics grows, driven by advancements in personalized medicine and rare diseases, the biologics contract development market continues to expand, with companies focusing on regulatory compliance, innovation, and cost-effective solutions.

Biologics Contract Development Market- Market Dynamics

Rising demand for personalized medicine driving biologics contract development growth.

The rising demand for personalized medicine is a significant driver for the biologics contract development market. Personalized medicine tailors' treatments to individual genetic profiles, improving efficacy and reducing adverse effects. According to the U.S. National Institutes of Health (NIH), the global market for personalized medicine is projected to reach $3.5 trillion by 2025.

As biological therapies are central to personalized medicine, the need for specialized contract development services grows. The increasing prevalence of genetic disorders and cancer further fuels demand for biologics, with the NIH estimating that about 1 in 10 people globally are living with a rare disease, many requiring biological treatments. These factors have pushed biopharma companies to partner with contract development organizations to access the necessary expertise and scale production efficiently.

Biologics Contract Development Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.94% over the forecast period (2025-2032)

Based on Service Type segmentation, Contract Manufacturing was predicted to show maximum market share in the year 2024

Based on Biologics Type segmentation, Monoclonal Antibodies were the leading Biologics Type in 2024

Based on region, North America was the leading revenue generator in 2024

Biologics Contract Development Market- Segmentation Analysis:

The Global Biologics Contract Development Market is segmented based on Service Type, Biologics Type, End-User, and Region.

The market is divided into three categories based on Service Type: Contract Research, Contract Manufacturing, and Contract Testing. The most dominant segment in the biologics contract development market is Contract Manufacturing. This segment has seen substantial growth due to the increasing demand for large-scale production of biological drugs, including monoclonal antibodies and vaccines. Contract manufacturing organizations (CMOs) provide biopharma companies with the expertise, facilities, and equipment needed to produce biologics efficiently while maintaining regulatory compliance. As biologic therapies require specialized processes, such as cell culture and fermentation, outsourcing these services helps companies reduce costs and time-to-market. The need for scalable manufacturing solutions, particularly with the rise of personalized medicine and biological therapies for complex diseases, has solidified the importance of this segment.

The market is divided into four categories based on Biologics Type: Monoclonal Antibodies, Vaccines, Gene Therapies, and Recombinant Proteins. The most dominant segment in the biologics contract development market is Monoclonal Antibodies. This segment leads due to the growing demand for monoclonal antibodies (mAbs) in the treatment of various conditions, including cancer, autoimmune disorders, and infectious diseases. mAbs are highly specific, offering targeted therapies that provide better efficacy and fewer side effects compared to traditional drugs. With advancements in biotechnology, many new mAbs have been developed, contributing to their widespread use in personalized medicine. As a result, contract development organizations (CDOs) are increasingly focused on providing services for the development and manufacturing of mAbs, making this segment the most prominent in the biologics contract development market.

Biologics Contract Development Market- Geographical Insights

North America holds a significant share of the biologics contract development market, driven by the robust healthcare infrastructure, strong research capabilities, and the high demand for biologic therapies. The U.S. Food and Drug Administration (FDA) plays a critical role in regulating biologics, ensuring the safety and efficacy of treatments, which boosts confidence in the market. North America is home to several leading biopharma companies, academic institutions, and contract development organizations, making it a key hub for biologics development. The U.S. has a high incidence of chronic diseases, including cancer and autoimmune disorders, which further accelerates the demand for biologic treatments. Additionally, the region's healthcare policies support innovation and reimbursement for personalized medicine, attracting significant investments in biologics. The increasing trend of outsourcing manufacturing and development services to specialized CDOs also adds to the market's growth. With advancements in genomics and biotechnology, North America is positioned to continue leading in biologics development and contract services.

The United States plays a dominant role in the biologics contract development market, driven by its advanced healthcare system, leading pharmaceutical companies, and cutting-edge research institutions. The U.S. Food and Drug Administration (FDA) provides a well-established regulatory framework that ensures the safety and efficacy of biological products, fostering confidence in the market. The country has a high prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which propels the demand for biological treatments. Furthermore, the U.S. is a global leader in biotechnology and pharmaceutical innovation, with significant investments in personalized medicine, gene therapies, and monoclonal antibodies. The increasing trend of outsourcing biologic development and manufacturing to contract development organizations (CDOs) allows biopharma companies to reduce costs and focus on innovation. Moreover, the U.S. government's support for research funding and regulatory incentives further strengthens the market landscape. With a growing emphasis on precision medicine, the biologics contract development market in the U.S. is expected to continue its strong growth trajectory.

Biologics Contract Development Market- Competitive Landscape:

The competitive landscape of the biologics contract development market is marked by the presence of several key players focusing on advanced technologies, regulatory compliance, and cost-effective solutions. Companies like Lonza Group, WuXi AppTec, and Samsung Biologics lead the market with their extensive service offerings in biologic drug development, including process development, manufacturing, and clinical trial support. Lonza Group, for example, offers state-of-the-art facilities and expertise in large-scale biologics production, particularly for monoclonal antibodies. WuXi AppTec is known for its integrated services across drug discovery, development, and manufacturing, with a strong emphasis on personalized medicine. Samsung Biologics combines cutting-edge biomanufacturing capabilities with a focus on operational efficiency and regulatory adherence. These companies maintain strong relationships with pharmaceutical firms and biotechnology companies, positioning themselves as preferred partners in the biologic development space. Their ability to scale production, ensure quality control, and adapt to evolving regulatory standards continues to fuel their competitive advantage.

Recent Developments:

In February 2023, Lonza expanded its footprint in the U.S. with the establishment of a new laboratory focused on developing drugs in the early stages of clinical trials.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Lonza Group
  • WuXi AppTec
  • Samsung Biologics
  • Catalent
  • Boehringer Ingelheim
  • AbbVie
  • Fujifilm Diosynth Biotechnologies
  • CordenPharma
  • Samsung Biologics
  • Patheon (Thermo Fisher Scientific)
  • Merck KGaA
  • KBI Biopharma
  • Recipharm
  • Minaris Regenerative Medicine
  • Syngene International
  • Rentschler Biopharma
  • Almac Group
  • Emergent BioSolutions

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Contract Research
  • Contract Manufacturing
  • Contract Testing

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY BIOLOGICS TYPE- MARKET ANALYSIS, 2019 - 2032

  • Monoclonal Antibodies
  • Vaccines
  • Gene Therapies
  • Recombinant Proteins

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic & Research Institutions

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Biologics Contract Development Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Biologics Contract Development Market Snippet by Service Type
    • 2.1.2. Biologics Contract Development Market Snippet by Biologics Type
    • 2.1.3. Biologics Contract Development Market Snippet by End-User
    • 2.1.4. Biologics Contract Development Market Snippet by Country
    • 2.1.5. Biologics Contract Development Market Snippet by Region
  • 2.2. Competitive Insights

3. Biologics Contract Development Key Market Trends

  • 3.1. Biologics Contract Development Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Biologics Contract Development Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Biologics Contract Development Market Opportunities
  • 3.4. Biologics Contract Development Market Future Trends

4. Biologics Contract Development Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Biologics Contract Development Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Biologics Contract Development Market Landscape

  • 6.1. Biologics Contract Development Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Biologics Contract Development Market - By Service Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Service Type, 2024 & 2032 (%)
    • 7.1.2. Contract Research
    • 7.1.3. Contract Manufacturing
    • 7.1.4. Contract Testing

Biologics Contract Development Market - By Biologics Type

  • 7.2. Overview
    • 7.2.1. Segment Share Analysis, By Biologics Type, 2024 & 2032 (%)
    • 7.2.2. Monoclonal Antibodies
    • 7.2.3. Vaccines
    • 7.2.4. Gene Therapies
    • 7.2.5. Recombinant Proteins

8. Biologics Contract Development Market - By End-User

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
    • 8.1.2. Pharmaceutical Companies
    • 8.1.3. Biotechnology Companies
    • 8.1.4. Academic & Research Institutions

9. Biologics Contract Development Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Biologics Contract Development Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.2.7. The U.S.
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.2.7.4. U.S. Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.2.8. Canada
      • 9.2.8.1. Overview
      • 9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.8.3. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.2.8.4. Canada Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Biologics Contract Development Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.7. Germany
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.7.4. Germany Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.8. UK
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.8.4. UK Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.8.5. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.9.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.10. Italy
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.3. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.10.4. Italy Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.10.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.11. Spain
      • 9.3.11.1. Overview
      • 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.3. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.11.4. Spain Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.11.5. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.12. The Netherlands
      • 9.3.12.1. Overview
      • 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.3. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.12.4. The Netherlands Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.12.5. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.13. Sweden
      • 9.3.13.1. Overview
      • 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.3. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.13.4. Sweden Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.13.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.14. Russia
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Russia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.14.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.15. Poland
      • 9.3.15.1. Overview
      • 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.15.3. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.15.4. Poland Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.16. Rest of Europe
      • 9.3.16.1. Overview
      • 9.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.16.3. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.16.4. Rest of the Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.16.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Biologics Contract Development Key Manufacturers in Asia Pacific
    • 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.4.5. APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.4.6. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.7.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.8. India
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.8.4. India Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.8.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.9. Japan
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.9.4. Japan Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.10. South Korea
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.10.4. South Korea Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.11. Australia
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Australia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.12.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.13. Thailand
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Thailand Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.13.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.14. Philippines
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Philippines Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.15. Rest of APAC
      • 9.4.15.1. Overview
      • 9.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.15.3. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.15.4. Rest of APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.5. Latin America (LATAM)
    • 9.5.1. Overview
    • 9.5.2. Biologics Contract Development Key Manufacturers in Latin America
    • 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.5.5. LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.5.6. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.7. Brazil
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Brazil Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.8. Mexico
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Mexico Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.9. Argentina
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Argentina Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.10. Colombia
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Colombia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.11. Rest of LATAM
      • 9.5.11.1. Overview
      • 9.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.11.3. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.11.4. Rest of LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa (MEA)
    • 9.6.1. Overview
    • 9.6.2. Biologics Contract Development Key Manufacturers in the Middle East and Africa
    • 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.6.5. MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.6.6. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.7. Saudi Arabia
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.7.4. Saudi Arabia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.8. UAE
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. UAE Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.8.4. UAE Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.8.5. UAE Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.9. Israel
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Israel Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.10. Turkey
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Turkey Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.11. Algeria
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Algeria Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.12. Egypt
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Egypt Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.13. Rest of MEA
      • 9.6.13.1. Overview
      • 9.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.13.3. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.13.4. Rest of MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Biologics Contract Development Industry

  • 10.1. Competitive Dashboard
    • 10.1.1. Competitive Benchmarking
    • 10.1.2. Competitive Positioning
  • 10.2. Company Profiles
    • 10.2.1. Lonza Group
    • 10.2.2. WuXi AppTec
    • 10.2.3. Samsung Biologics
    • 10.2.4. Catalent
    • 10.2.5. Boehringer Ingelheim
    • 10.2.6. AbbVie
    • 10.2.7. Fujifilm Diosynth Biotechnologies
    • 10.2.8. CordenPharma
    • 10.2.9. Samsung Biologics
    • 10.2.10. Patheon (Thermo Fisher Scientific)
    • 10.2.11. Merck KGaA
    • 10.2.12. KBI Biopharma
    • 10.2.13. Recipharm
    • 10.2.14. Minaris Regenerative Medicine
    • 10.2.15. Syngene International
    • 10.2.16. Rentschler Biopharma
    • 10.2.17. Almac Group
    • 10.2.18. Emergent BioSolutions

11. 360 Degree AnalystView

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us